Company Profile
HitGen is a drug discovery research platform for small molecules and nucleic acid drugs in China and globally. Its technology platform includes DNA-encoded library technology. Its portfolio also includes fragment-based drug discovery and structure-based drug design technologies, emerging technology platforms for synthetic therapeutic oligonucleotide technology, and targeted protein degradation technology.
The company's product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor. Its portfolio also includes HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor, HG153 a Menin-MLL tablet, HG248, HG 381, an immune-oncology agonist for cancer HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation, and HGP1069, a ROCK2 inhibitor eye drop
Target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. It also focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.